10 completed, 3 recruiting, 2 active not recruiting, 2 terminated. 18 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 18 | Completed 10, Recruiting 3, Active not recruiting 2, Terminated 2, Unknown 1 |
| Phase 1 | 2 | Completed 2 |
Follow Cocaine Use Disorder: new trials by email Literature Review of Cocaine Use Disorder trials Research Report on Cocaine Use Disorder
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| An Open-Label Tirzepatide Trial for Comorbid Obesity and Stimulant Use Disorder Tirzepatide - Obesity, Methamphetamine Use Disorder | Phase 2 | Active not recruiting | University of Texas Southwestern Medical Center | 45 | 2026-08-19 | 2026-10-29 |
| Efficacy and Safety of Sustained-release Dexamphetamine in Patients With Moderate to Severe Cocaine Use Disorder Sustained-release Dexamphetamine, Placebo - Cocaine Use Disorder | Phase 2 | Recruiting | Parnassia Addiction Research Centre | 204 | 2026-04-22 | 2026-05-29 |
| Repurposing Semaglutide for the Treatment of Cocaine Use Disorder Semaglutide, Placebo, cognitive behavioral therapy (CBT). - Cocaine Use Disorder | Phase 2 | Recruiting | The University of Texas Health Science Center, Houston | 75 | 2026-01-15 | 2026-03-19 |
| Evaluation Of Semaglutide in Adults With Cocaine Use Disorder With and Without HIV Semaglutide, Placebo - Cocaine Use Disorder, HIV | Phase 2 | Active not recruiting | University of Maryland, Baltimore | 40 | 2025-08-07 | 2026-09-10 |
| Ketamine and Neurofeedback-Training: Effects on Neuroplasticity in Cocaine Addiction Ketamine, Placebo, real-time fMRI neurofeedback training - Cocaine Use Disorder, Cocaine Dependence | Phase 2 | Recruiting | Dr. med. Marcus Herdener | 120 | 2024-02-05 | 2024-12-20 |
| Enhanced Digital-Chemosensory-Based Olfactory Training for Remote Management of Substance Use Disorders EDITOR (CBOT with olfactory stimulants, OFC tasks & remote monitoring of treatment compliance), CBOT with olfactory stimulants & OFC tasks, CBOT Sham - Substance Use Disorders, Opioid Use Disorder | Phase 2 | Unknown | Evon Medics LLC | 300 | 2023-07-07 | 2024-05-30 |
| Extended-Release Naltrexone and Monthly Extended-Release Buprenorphine for Cocaine Use Disorder (CURB-2) Extended-Release Naltrexone, Extended Release Buprenorphine, Placebo (PLB) Injectable matched to XR-NTX - Cocaine Use Disorder | Phase 2 | Completed | University of Texas Southwestern Medical Center | 427 | 2023-04-18 | 2025-10-21 |
| Cariprazine for Comorbid Cocaine and Opioid Use Disorder Cariprazine 1.5 MG, Placebo - Opioid-use Disorder, Cocaine Use Disorder | Phase 2 | Completed | Kyle Kampman | 26 | 2022-08-05 | 2026-01-23 |
| Pioglitazone as an Adjunct to Cognitive-Behavioral Therapy for Cocaine Relapse Prevention Cognitive Behavioral Therapy (CBT), Pioglitazone, Placebo - Cocaine Use Disorder | Phase 2 | Completed | The University of Texas Health Science Center, Houston | 61 | 2021-08-23 | 2026-09-21 |
| Exenatide for Treating Cocaine Use Disorder Exenatide 2 mg [Bydureon], Drug Counseling - Cocaine Use Disorder | Phase 1 / Phase 2 | Completed | The University of Texas Health Science Center, Houston | 3 | 2021-06-24 | 2022-06-27 |
| TDCS to Reduce Craving in Cocaine Addiction- Phase 2 Study transcranial direct current stimulator (tDCS), Cognitive Reappraisal - Cocaine Use Disorder, Cocaine Dependence | Phase 2 | Completed | Soterix Medical | 60 | 2020-09-28 | 2024-11-18 |
| A Study to Evaluate EMB 001 in Subjects With Cocaine Use Disorder EMB-001, EMB-001 Placebo - Cocaine Use Disorder | Phase 2 | Completed | Embera NeuroTherapeutics, Inc. | 82 | 2020-07-29 | 2026-09-21 |
| Cariprazine Effects on Brain and Behavior in Cocaine Use Disorder Cariprazine Oral Capsule [Vraylar], Placebo oral capsule - Cocaine Use Disorder | Phase 2 | Terminated | Anna Rose Childress, Ph.D. | 14 | 2018-04-04 | 2020-09-09 |
| Treatment With Lorcaserin for Cocaine Use: The TLC Study lorcaserin, Placebo Oral Tablet, Substance use counseling - Cocaine Use Disorder | Phase 2 | Terminated | Glenn-Milo Santos | 22 | 2018-01-01 | 2023-08-14 |
| Role of the Orexin Receptor System in Stress, Sleep and Cocaine Use suvorexant, Placebo (for suvorexant) - Cocaine Use Disorder, Anxiety | Phase 2 | Completed | The University of Texas Health Science Center, Houston | 20 | 2016-05-01 | 2019-12-11 |
| Trial Of NS2359 For The Treatment of Cocaine Dependence NS2359, placebo - Cocaine Use Disorder | Phase 2 | Completed | University of Pennsylvania | 55 | 2016-05-01 | 2021-05-24 |
| Neural Substrates of Emotion: Impact of Cocaine Dependence Oxytocin, Placebo - Cocaine Use Disorder | Phase 2 | Completed | Medical University of South Carolina | 138 | 2015-07-01 | 2021-10-21 |
| PPARγ Agonist Treatment for Cocaine Dependence Pioglitazone, Placebo, Therapy - Cocaine Use Disorder, Alcohol Use Disorder | Phase 1 / Phase 2 | Completed | The University of Texas Health Science Center, Houston | 30 | 2012-08-01 | 2018-04-26 |
Cocaine-Related Disorders (5) · Opioid-Related Disorders (3) · Alcoholism (2) · Anxiety Disorders (1) · Behavior, Addictive (1) · Obesity (1) · Overweight (1) · Recurrence (1) · Sexual Behavior (1) · Substance-Related Disorders (1)
Mental Disorders (10) · Chemically-Induced Disorders (9) · Substance-Related Disorders (8) · Narcotic-Related Disorders (3) · Alcohol-Related Disorders (2) · Behavior (2) · Pathological Conditions, Signs and Symptoms (2) · Body Weight (1) · Compulsive Behavior (1) · Disease Attributes (1) · Impulsive Behavior (1) · Nutrition Disorders (1) · Nutritional and Metabolic Diseases (1) · Overnutrition (1) · Pathologic Processes (1)
Starch (3) · Cognitive Behavioral Therapy (2) · Pioglitazone (2) · cariprazine (2) · semaglutide (2) · Ecological Momentary Assessment (1) · Exenatide (1) · GSK372475 (1) · Ketamine (1) · Oxytocin (1) · Saline Solution (1) · Therapeutics (1) · Tirzepatide (1) · lorcaserin (1) · phospholamban (1)
The University of Texas Health Science Center, Houston (5) · University of Texas Southwestern Medical Center (2) · Anna Rose Childress, Ph.D. (1) · Dr. med. Marcus Herdener (1) · Embera NeuroTherapeutics, Inc. (1) · Evon Medics LLC (1) · Glenn-Milo Santos (1) · Kyle Kampman (1) · Medical University of South Carolina (1) · Parnassia Addiction Research Centre (1) · Soterix Medical (1) · University of Maryland, Baltimore (1) · University of Pennsylvania (1)
United States (16) · Netherlands (1) · Switzerland (1)
Joy M Schmitz, PhD (2) · Luba Yammine, PhD (2) · Abhishek Datta, PhD (1) · Aimee L McRae-Clark, PharmD (1) · Anna Rose Childress, PhD (1) · Bruce McCarthy, MD (1) · Charles Nwaokobia (1) · Edwin Chapman, MD (1) · Evaristus Nwulia, MD (1) · Glenn-Milo Santos, PhD, MPH (1) · Joy Schmitz, PhD (1) · Madhukar Trivedi, MD (1) · Manish Jha, M.B.B.S. (1) · Marc Fishman, MD (1) · Scott D Lane, PhD (1)
PMID 34265007, PMID 37579116, PMID 40360074, PMID 40999531, PMID 42161545
P50DA009262 (1), R01DA048026 (1), R01DA062720 (1), R34DA042161 (1), R44DA056156 (1), U01DA038879 (1), UG1DA020024 (1)